Results

125 patients aged 50 to 92 (median 74 years, lower quartile 70, upper quartile 78 years) were included.

For the whole group, serum testosterone values ranged from 14 ng/dl (0.5 nmol/l, lowest reportable result) to 107 ng/dl (3.7 nmol/l), median 37 ng/dl (1.3 nmol/l), lower quartile 32 ng/dl (1.1 nmol/l), upper quartile 58 ng/dl (2.0 nmol/l).

According to those results, considering castrate level of 20 ng/dl (=0.694 nmol/l), only 7% of patients on LHRH treatment and 2/10 patients after surgical castration could be classified to castrate state of disease. Considering castrate level of 50 ng/dl (1.735 nmol/l), 66% of patients on chemical castration and 8/10 patients after surgical castration would comply.

Testosterone measurement results, according to LHRH agonist, are presented in Table 4. According to analysis of variance, differences between groups of patients, treated with different LHRH agonists, were not significantly different (F=0.69, p=0.5).

LHRH formulation

N

TST:min-max

TST-median

TST-75%

TST-90%

triptorelin 11.25 mg

53

20-98

37

58

72

goserelin 10.8 mg

41

14-107

37

52

69

leuprolide 22.5 mg

21

14-84

49

63

72

Table 4. Testosterone measurement results with Abbot Architect assay in patients on different 3-month LHRH agonists. Samples were taken immediately before next injection. TST - testosterone. Units: ng/dl (1,73nmol/L=50 ng/ dl). Differences between different LHRH formulations were not statistically significant.

Table 4. Testosterone measurement results with Abbot Architect assay in patients on different 3-month LHRH agonists. Samples were taken immediately before next injection. TST - testosterone. Units: ng/dl (1,73nmol/L=50 ng/ dl). Differences between different LHRH formulations were not statistically significant.

0 0

Post a comment